FTC Affiliate Disclosure: This article may contain affiliate links. If you enroll through a link in this article, a commission may be earned at no additional cost to you. This does not influence the clinical information presented.
When the New York Times profiled MEDVi on April 2, 2026, the headline was about AI and a solo founder building a $1.8 billion telehealth company. The number that got less attention was arguably more significant for men's health: 50,000 customers in the first month of MEDVi's men's health expansion. The QUAD erectile dysfunction product, launched in February 2026, is growing fast enough that it is expected to surpass MEDVi's GLP-1 weight-loss business — which generated $401 million in 2025 — within four months.
That kind of adoption pace does not happen in a vacuum. It reflects both genuine demand for accessible ED treatment and aggressive marketing by a company that is simultaneously navigating an FDA warning letter, litigation involving its clinical partners, and questions about its advertising practices. For men evaluating QUAD, the clinical questions about the formulation are inseparable from the questions about the company behind it.
This article covers both. For a broader look at MEDVi's telehealth ED model, platform structure, and enrollment process, see our full QUAD by MEDVi telehealth ED treatment analysis.
The MEDVi Story: Why This Company Is in the News
MEDVi's founder, Matthew Gallagher, launched the company in September 2024 with $20,000 and more than a dozen AI tools. According to financials the Times verified directly, MEDVi generated $401 million in 2025 revenue with a 16.2 percent net profit margin — running the entire operation with two full-time employees, himself and his brother Elliot. The company now projects $1.8 billion for 2026. Forbes, PYMNTS, and Inc. covered the story within hours.
At the same time, the investigative layer of the story surfaced. The FDA issued MEDVi a warning letter in February 2026 for misbranding violations on its website — specifically, marketing language that falsely implied FDA approval of compounded products. More than 30 other telehealth companies received similar warnings. MEDVi's clinical partner OpenLoop Health disclosed a data breach in January 2026 affecting up to 1.6 million patient records. A class-action complaint against OpenLoop and Triad Rx questions whether compounded oral tirzepatide has any viable absorption pathway.
None of these regulatory issues are specifically about QUAD. The FDA warning addressed GLP-1 marketing. The breach and lawsuits involve infrastructure partners. But they reflect the environment in which MEDVi operates — and they are context any man should have before enrolling in a MEDVi program in April 2026.
MEDVi holds active LegitScript certification, has more than 11,400 Trustpilot reviews at 4.4 to 4.5 stars, and its financials are NYT-verified. The company is not a scam. It is a legitimate, fast-growing platform with real credentials and real unresolved questions.
What MEDVi QUAD Actually Contains
QUAD by MEDVi is a compounded sublingual prescription medication — a dissolvable liquid placed under the tongue to bypass the digestive system and deliver medication directly into the bloodstream. It contains four active ingredients:
Sildenafil (Viagra) — a PDE5 inhibitor that relaxes smooth muscle and increases blood flow. Typical oral onset is 30 to 60 minutes. Sublingual delivery may be faster.
Tadalafil (Cialis) — a PDE5 inhibitor with a longer duration of action, up to 36 hours. This provides the extended window in the QUAD formulation.
PT-141 (Levitra) — a third PDE5 inhibitor with a slightly different selectivity profile. Including two PDE5 inhibitors in one formulation is the aspect that raises the most clinical questions.
L-Citrulline — a dopamine receptor agonist that works through the central nervous system to stimulate arousal. It was approved for ED in Europe under the brand name Uprima but was withdrawn from several markets due to limited efficacy and nausea side effects.
Each ingredient has FDA approval as an individual compound. The four-ingredient combination is not FDA-approved as a finished product. This is the same regulatory status as all compounded medications — it is not unique to QUAD. An April 2026 claims evaluation published through Globe Newswire examined how QUAD's compounded prescription model, doctor-approval structure, and regulatory classification compare to what consumers should verify before enrolling in any telehealth ED program.
The sublingual delivery method is a key part of what differentiates QUAD from standard oral ED tablets. But how much of that difference is clinically meaningful versus marketing emphasis? Our evidence-based comparison of sublingual versus oral ED medication absorption covers the published pharmacokinetic research, including the 2016 Journal of Pharmaceutical Sciences study and the 2018 Frontiers in Pharmacology data on sublingual sildenafil.
The Clinical Questions That Matter
two PDE5 inhibitors in one formulation is not standard practice. Clinical guidelines for ED start with a single PDE5 inhibitor and adjust dosing before switching agents. Combining three is not reflected in published treatment guidelines. The theoretical rationale — different selectivity profiles and onset/duration windows providing broader coverage — has not been validated by clinical trials of this specific combination.
Cardiovascular screening becomes more important. All PDE5 inhibitors lower blood pressure through vasodilation. Three in one dose amplifies that effect. Men taking nitrates must not take any PDE5 inhibitor. Men with unstable cardiac conditions, recent stroke, or uncontrolled hypertension need thorough evaluation before considering this formulation.
L-Citrulline adds a CNS component with a known side effect profile. Nausea is dose-dependent and was significant enough in European clinical trials to affect patient adherence. The sublingual route may reduce nausea compared to oral delivery, but no published data confirms this for the QUAD-specific combination.
Sublingual delivery changes the math. Bypassing first-pass liver metabolism means faster onset and potentially higher effective concentrations than the same dose taken orally. Dosing calibration established for oral PDE5 inhibitors may not apply directly. The prescribing clinician should account for this difference.
The safety profile of any compounded multi-ingredient ED formulation depends on proper cardiovascular screening and a complete medication review — not just the delivery method. For a full breakdown of the regulatory framework, the specific drug interactions to verify, and a seven-point checklist to use before enrolling in any compounded ED program, see our compounded ED medication safety guide for 2026. And if you arrived here because your current ED medication isn't working anymore, our guide to why PDE5 inhibitors stop working covers the clinical reasons and the full treatment escalation pathway.
How QUAD Fits in the ED Treatment Hierarchy
First-line (Hims, Ro, Lemonaid): Single-ingredient generic sildenafil or tadalafil, $2 to $10 per dose. Standard starting point for men who have not tried PDE5 therapy. If you have never taken an ED medication, start here.
MEDVi QUAD: Four-ingredient compounded sublingual formulation. Positioned for men who want faster onset, longer duration, and multi-mechanism coverage. Monthly subscription pricing — verify current rates on the MEDVi website.
Injection therapy (Tri-Mix/Quad-Mix): Intracavernosal injection. Gold standard for severe or treatment-resistant ED, 70 to 85 percent success rates. QUAD is positioned before injections in the treatment progression, not as a replacement for severe cases.
Whether QUAD delivers meaningfully better results than a single optimized PDE5 inhibitor has not been proven by published head-to-head data. The combination is novel. Novel is not automatically better.
The Platform Behind the Product
QUAD is sold through the same MEDVi telehealth platform that runs the GLP-1 business. That means the same structural features apply — and the same concerns:
Clinical care comes through OpenLoop Health and CareValidate partner networks. MEDVi employs two people total. The FDA warning letter addressed marketing practices across the platform. Trustpilot shows 4.4 to 4.5 stars across 11,400-plus reviews, while ConsumerAffairs shows 3.6 across roughly 1,600 — with billing complaints (auto-renewal confusion, cancellation difficulty, refund disputes) as the dominant negative pattern. Programs auto-renew and require 72-hour cancellation notice.
The OpenLoop data breach in January 2026 is relevant here. If you enroll in any MEDVi program using OpenLoop's clinical services, your health information is processed through their systems. That infrastructure partner has confirmed at least 68,160 affected individuals in Texas and faces multiple class-action lawsuits.
What to Ask Before Enrolling
Have you tried a single PDE5 inhibitor first? If not, starting with one medication at an optimized dose is the standard clinical approach. A four-ingredient combination may be premature.
Is this formulation appropriate for your heart health? Three vasodilators in one dose demand more careful cardiovascular screening than a single agent. Be thorough about your cardiac history, blood pressure, and current medications — especially nitrates.
What evidence supports the four-ingredient combination? Each ingredient has individual FDA approval. The combination does not. Ask your clinician directly what published evidence supports using all four together.
Do you understand the billing terms? MEDVi programs auto-renew. You must cancel at least 72 hours before your next billing date. Read the refund policy in full before paying.
Frequently Asked Questions
What is MEDVi QUAD?
A compounded sublingual prescription containing sildenafil, tadalafil, PT-141, and L-Citrulline for erectile dysfunction. Placed under the tongue for faster absorption. Not FDA-approved as a finished product.
Why is MEDVi in the news right now?
The New York Times profiled MEDVi on April 2, 2026, reporting $401 million in 2025 revenue with two employees and a $1.8 billion 2026 projection. Simultaneously, the company faces an FDA warning letter, its clinical partner OpenLoop has a data breach affecting up to 1.6 million patients, and pending litigation questions the efficacy of some compounded products in the OpenLoop network.
Is MEDVi QUAD FDA-approved?
No. It is a compounded medication. Each individual ingredient has FDA approval. The four-ingredient combination has not been reviewed or approved by the FDA as a finished product.
Is it safe to take two PDE5 inhibitors at once?
This requires careful cardiovascular screening. All PDE5 inhibitors lower blood pressure. Three in one dose increases that effect. Men taking nitrates, alpha-blockers, or hypertension medications need thorough evaluation. Discuss your full medication list with the prescribing clinician.
How does QUAD compare to Hims or Roman for ED?
Hims and Roman prescribe single-ingredient generics at $2 to $10 per dose — standard first-line treatment. QUAD is a more complex formulation positioned for men who did not get adequate results from single-agent therapy. Most guidelines recommend starting with one PDE5 inhibitor before moving to combinations.
What are QUAD's side effects?
Headache, flushing, nasal congestion, dizziness, visual changes (PDE5 effects) plus nausea from L-Citrulline. The sublingual route may produce faster onset of both therapeutic effects and side effects. Report chest pain, prolonged erection (4-plus hours), or sudden vision/hearing changes immediately.
This article is for informational purposes only and does not constitute medical advice. ED medications are prescription drugs requiring clinical evaluation. Compounded medications are not FDA-approved finished products. Consult a licensed healthcare professional before starting any medication.
TriCountyUrology.org Editorial Team | Published April 2026
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.